Evidence map›Paper›PMID 39220218›Full record

ArticleTransplantation direct2024

Anti-HLA Class II Antibodies Are the Most Resistant to Desensitization in Crossmatch-positive Living-donor Kidney Transplantations: A Patient Series.

Annelies E de Weerd, Dave L Roelen, Michiel G H Betjes, Marian C Clahsen-van Groningen, Geert W Haasnoot, Marcia M L Kho, Marlies E J Reinders, Joke I Roodnat, David Severs, Gonca E Karahan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation direct, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Annelies E de WeerdDepartment of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0001-5134-2025
Dave L RoelenDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
Michiel G H BetjesDepartment of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands.
Marian C Clahsen-van GroningenDepartment of Pathology, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands.
Geert W HaasnootDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
Marcia M L KhoDepartment of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands.
Marlies E J ReindersDepartment of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands.
Joke I RoodnatDepartment of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands.
David SeversDepartment of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands.
Gonca E KarahanDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
Jacqueline van de WeteringDepartment of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In HLA-incompatible kidney transplantation, the efficacy of desensitization in terms of anti-HLA antibody kinetics is not well characterized. We present an overview of the course of anti-HLA antibodies throughout plasma exchange (PE) desensitization in a series of crossmatch-positive patients. Methods: All consecutive candidates in the Dutch HLA-incompatible kidney transplantation program between November 2012 and January 2022 were included. The eligibility criteria were a positive crossmatch with a living kidney donor and no options for compatible transplantation. Desensitization consisted of 5-10 PE with low-dose IVIg. Results: A total of 16 patient-donor pairs were included. Patients had median virtual panel-reactive antibody of 99.58%. Cumulative donor-specific anti-HLA antibody (cumDSA) mean fluorescence intensity (MFI) was 31 399 median, and immunodominant DSA (iDSA) MFI was 18 677 for class I and 21 893 for class II. Median anti-HLA antibody MFI response to desensitization was worse in class II as compared with class I ( Conclusions: Patients with class II DSA, and particularly those directed against HLA-DQ locus, were difficult to desensitize.

Identifiers

PMID39220218
PMCPMC11365629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.